$500,000 Michael F. Price Grant Awarded to MD Anderson for Gastric Cancer Clinical Trial
In a remarkable development, a significant grant of $500,000 has been awarded by The DeGregorio Family Foundation, with the support of the Torrey Coast Foundation, to Dr. Katy Rezvani, MD, PhD, who is leading the charge at the esteemed MD Anderson Cancer Center. This funding is dedicated to crucial research focusing on gastric cancer, particularly for patients challenged by stage IV complications.
Advancing Innovative Clinical Trials
MD Anderson, under Dr. Rezvani and Dr. Brian Badgwell, Professor of Surgical Oncology, is embarking on a cutting-edge clinical trial that seeks to enhance treatment outcomes for patients with gastric cancer that has metastasized to the peritoneum. The peritoneum, the abdominal lining, often complicates treatment, as conventional chemotherapy struggles to penetrate and affect tumors in this area.
Understanding the Challenges of Peritoneal Cancer
The complexities of peritoneal cancer present a difficult landscape for patients. The condition can lead to severe complications like bowel obstruction and the accumulation of fluid in the abdomen. Typically, surgical intervention, which may involve removing the stomach, is currently the primary treatment modality. However, the efficacy of such drastic measures for stage IV patients remains uncertain.
Innovative Treatment Strategies
This pioneering trial integrates three potent approaches: surgical tumor removal, localized delivery of chemotherapy directly to the peritoneal cavity, and an advanced immunotherapy employing engineered natural killer (NK) cells.
The Role of Natural Killer Cells
Natural killer cells are crucial components of the immune system, recognized for their capability to target and eliminate abnormal cells. Within this trial, these cells are enhanced using three strategic modifications: they are armed with receptors to specifically target TROP2, a protein prevalent on gastric cancer cells; given IL-15 to increase their longevity; and modified to circumvent suppression by the tumor’s environment. These enhancements aim to ensure that NK cells maintain their effectiveness even in the challenging circumstances found deep within the abdomen.
Focus on Future Insights
Moreover, this research initiative does not solely focus on treatments but also emphasizes exploration. The team plans to analyze tissue samples to identify new therapeutic targets while determining which patient profiles might benefit most from this aggressive treatment strategy. Ultimately, their goal is to improve survival rates and broaden the available treatment options for patients grappling with this severe form of cancer.
Dr. Rezvani expressed deep gratitude for the support from The DeGregorio Family Foundation, stating, "We are thankful for the generous $500K grant towards our project. It will play a pivotal role in propelling our clinical trial forward." Lynn DeGregorio, the foundation's President and Founder, also voiced her support: "We are thrilled to assist in the first human trial featuring an off-the-shelf, cord blood-derived NK cell therapy, designed with a chimeric antigen receptor specifically for patients enduring gastric cancer with peritoneal metastases."
The Impact of Gastric and Esophageal Cancers
Globally, gastric and esophageal cancers posed a significant health threat, causing over 1.3 million deaths in the past year alone. The prognosis for patients diagnosed with these cancers remains dire, predominantly due to the malignancies' resistance to chemotherapy and their propensity to spread rapidly.
Supporting Innovative Research
This significant grant underscores the DeGregorio Family Foundation's commitment to funding transformative research. Established in 2006 after the tragic loss of a family member to stomach cancer, the foundation has allocated over $13 million to fostering innovative research to combat gastric and esophageal cancers. It stands out as the only public foundation devoted entirely to supporting research grants aimed at curing these challenging diseases.
For those inspired to contribute, additional information can be found through necessary channels.
Frequently Asked Questions
What is the focus of the MD Anderson clinical trial funded by the grant?
The trial aims to improve treatment outcomes for patients with stage IV gastric cancer that has spread to the peritoneum.
Who is leading the clinical trial at MD Anderson?
Dr. Katy Rezvani and Dr. Brian Badgwell are leading the innovative clinical trial at MD Anderson.
What are the main treatment strategies being tested in the trial?
The trial combines surgical tumor removal, localized chemotherapy delivery, and advanced NK cell immunotherapy.
Why are natural killer cells significant in cancer treatment?
Natural killer cells play a vital role in targeting and destroying abnormal cells, making them key players in immunotherapy.
What is the history of the DeGregorio Family Foundation?
The foundation was established in 2006 to fund research for gastric and esophageal cancers after a family member succumbed to stomach cancer.
